Convicted Pharma Fraudster Seeks Post-Trial Acquittal

Law360, New York (November 11, 2010, 3:01 PM EST) -- A pharmaceutical company CEO convicted last year of fraudulently marketing one of his company’s drugs for a deadly lung disease has asked a judge to consider testimony from a new witness he says will establish his innocence.

Testimony from biostatistics expert Steven N. Goodman will prove that InterMune Inc. CEO Dr. W. Scott Harkonen made a reasonable inference from the statistical evidence that his company’s new drug Actimmune could effectively treat patients suffering from idiopathic pulmonary fibrosis, his attorney Mark Haddad claimed in a motion filed...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.